Johnson & Johnson (NYSE:JNJ) Holdings Boosted by Richwood Investment Advisors LLC

Richwood Investment Advisors LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 12.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,648 shares of the company’s stock after purchasing an additional 396 shares during the period. Richwood Investment Advisors LLC’s holdings in Johnson & Johnson were worth $528,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. M Holdings Securities Inc. purchased a new position in Johnson & Johnson during the 4th quarter worth approximately $354,000. Banco de Sabadell S.A grew its holdings in shares of Johnson & Johnson by 1.3% during the 4th quarter. Banco de Sabadell S.A now owns 14,660 shares of the company’s stock valued at $2,119,000 after acquiring an additional 181 shares in the last quarter. Guardian Partners Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at $13,533,000. KLP Kapitalforvaltning AS purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at $151,535,000. Finally, AXQ Capital LP purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at $1,537,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on JNJ shares. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Stifel Nicolaus decreased their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Barclays upped their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Finally, Citigroup decreased their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $163.40 on Friday. The company has a market cap of $393.76 billion, a PE ratio of 24.57, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average of $156.99 and a 200-day moving average of $156.25. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.